Hepatitis: Research
(asked on 3rd February 2025) - View Source
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into Hepatitis B in the 2023-24 financial year; and which public bodies provided that funding.
Answered by
Feryal Clark
Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). NIHR funds, enables, and delivers high-quality research to improve patient care and public health and supports liver research through a range of funding programmes, training, support for researchers and facilities.
UKRI delivers a substantial portfolio of researcher-led projects. This includes biological, physiological, mechanistic and clinical studies to investigate the causes and underpin the development of treatments for a variety of liver conditions/diseases.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
UIN |
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
28175 | Hepatitis B | NIHR allocated £220,741 for research concerning Hepatitis B and Hepatitis C research in 2023-24. | The total commitment across UKRI in 2023-24 for Hepatitis B research was £1,810,412 for 2 awards from MRC. |
28176 | Hepatitis C |
| UKRI did not commit any specific funding for obstructive Hepatitis C research in 2023-24. |
28177 | Hepatocellular carcinoma | NIHR allocated £1,633,698 for research concerning hepatocellular carcinoma research in 2023-24. | The total commitment across UKRI in 2023-24 for hepatocellular carcinoma research was £2,758,044 for 5 awards (1 award from MRC and 4 awards from centrally managed UKRI schemes). |
28178 | Cholangiocarcinoma | NIHR did not allocate any funds concerning cholangiocarcinoma research in 2023-24 | The total commitment across UKRI in 2023-24 for cholangiocarcinoma research was £187,096 (1 award from centrally managed UKRI schemes). The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) committed £17,595 in 2023-24 for cholangiocarcinoma research for 1 award. |
28179 | Biliary cirrhosis | NIHR did not allocate any funds concerning primary biliary cirrhosis research in 2023-24 | UKRI did not commit any funding for primary biliary cirrhosis research in 2023-24. |
28180 | Sclerosing cholangitis | NIHR did not allocate any funds concerning primary sclerosing cholangitis research in 2023-24 | UKRI did not commit any funding for primary sclerosing cholangitis research in 2023-24. |
28181 | Autoimmune hepatitis | NIHR did not allocate any funds concerning autoimmune hepatitis research in 2023-24 | UKRI did not commit any funding for autoimmune hepatitis research in 2023-24. |
28182 | Non-alcoholic fatty liver disease | NIHR allocated £151,511 for research concerning non-alcoholic and alcoholic fatty liver disease research in 2023-24. | The total commitment across UKRI in 2023-24 for non-alcoholic fatty liver disease research was £3,647,138 for 4 awards (1 award from Innovate UK; 2 awards from MRC, 1 award from centrally managed UKRI schemes). |
28183 | Alcoholic fatty liver disease | UKRI did not commit any funding for alcoholic fatty liver disease research in 2023-24. |